Sonnerie VC's investment thesis: operator-led, pre-seed and seed capital and the first institutional check for university spinouts in healthcare, life sciences, therapeutics, and medical devices.

Thesis

The clearest tone
in a noisy market.

Sonnerie is the ring, the sound made to be heard above everything else. We detect the earliest signal of a breakthrough and amplify it before the market can.

Every company worth building starts as a signal almost no one can hear.

In a lab, a result holds. A clinician notices a pattern. A scientist files a patent and returns to the bench. None of it looks like a company yet. It looks like noise.

We listen differently. We tune to the earliest moment, pre-seed, pre-traction, often pre-company, and we have the scientific and operating literacy to act on what we hear. Then we amplify: first capital, a board seat, the help to carry a finding to a fundable company. From signal to scale.

Fund I

A focused first fund.

Sonnerie VC Fund I is a pre-seed fund in New York, backing U.S. healthcare and technology startups in regulated markets. Operator-led, it draws on the GPs’ on-thesis $1.3B strategic exit in this space. Born from the Columbia alumni network, and focused on impactful innovation.

At Sonnerie VC, our mission is to amplify bold ideas. We back visionary founders building transformative solutions with lasting impact, empowering them with capital, operational insight, and a global network to scale their companies from signal to success.

What we believe

Five convictions.

The lab is the alpha.
The boundary between university research and company formation is the most inefficient market in venture. Edge comes from being early and literate there.
Operators beat spectators.
Scientific founders don’t need passive money. We take board and advisory seats and earn our place on the cap table.
Regulation is a moat.
In healthcare, the compliance path is where teams stall, and where the well-advised build durable advantage. We design it early.
Conviction over consensus.
Pre-seed rewards the courage to write the first check on incomplete information. We back the founder before the signal is obvious.
Impact compounds.
We invest where success means healthier, longer lives, and where returns and mission point the same way.
The mandate

Deliberately narrow.

Stage

Pre-seed and seed. Often the first check; we follow on.

Sectors

Therapeutics, devices, life sciences, regulated health tech.

Source

University spinouts and tech transfer.

Geography

United States. Based in New York.

Briefly

For the record.

What is Sonnerie?
An operator-led, pre-seed and seed venture firm. The first institutional check into university healthcare spinouts.
What stage?
Pre-seed and seed, the first institutional check at formation, with conviction through the seed round.
What do you back?
Therapeutics, medical devices, life sciences and diagnostics, and regulated health technology.
Where?
Across the United States, from New York, alongside university tech transfer offices and founders.

The rest, we share in person.

If you’re building it,
we’re already listening.

Get in touch → How we work